April 12, 2019 10:43 AM EDTUpdated May 30, 12:00 PM
Financing
China

This Chi­nese phar­ma filed for an IPO last Sep­tem­ber. Sev­en months and a $283M in­vest­ment lat­er, they are back at the HKEX

Amber Tong

A sto­ried Chi­nese phar­ma play­er is aim­ing for a sec­ond shot at join­ing some pre-rev­enue biotechs on the Hong Kong Stock Ex­change, in an IPO …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

A service from the Financial Times